Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.

@article{Harms2013CurrentSO,
  title={Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.},
  author={Nathan V. Harms and Carol B. Toris},
  journal={Expert opinion on pharmacotherapy},
  year={2013},
  volume={14 1},
  pages={105-13}
}
INTRODUCTION Optic nerve and retinal diseases such as glaucoma, age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are significant public health concerns and have a momentous impact on patients' functional status and quality of life. These diseases are among the most common causes of visual impairment worldwide and account for billions of dollars in healthcare expenditures and lost productivity. The importance of adequate treatment of these conditions and the need for… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS